Novacyt Share Price

Novacyt competes in the Health Technology sector and Biotechnology industry. It is headquartered in Vélizy-Villacoublay, FR and is traded on the London Stock Exchange, through the symbol NCYT-LN.

GBX£419.20
1.60%
Previous Close:
GBX£4.19 0.016% (May 7th, 2021)

Latest Share Trading Activity for Novacyt

Day Open:
GBX£412.60(previous open GBX£4.21)
Day High:
GBX£436.50(previous high GBX£4.30)
Day Low:
GBX£412.60(previous low GBX£4.16)

About Novacyt

Company Description
Novacyt SAS engages in the development and sale of cancer and infectious disease diagnostic products. It operates through the Corporate and Diagnostics; and Molecular Products segments. The Corporate and Diagnostics segment includes diagnostic activities in laboratories, and the manufacturing and distribution of reagents and kits for bacterial and blood tests. The Molecular Products segment comprises of design, manufacture, and distribution of test kits for certain diseases in humans, animals and food products. The company was founded by Eric Peltier, Gerald Ulrich, and Jean-Pierre Crinelli on July 3, 2006 and is headquartered in Velizy-Villacoublay, France.
Chief Executive Officer (CEO)
Graham David Mullis
Website Address
http://www.novacyt.com
Postal Address
13, avenue Morane Saulnier Ile-de-France Vélizy-Villacoublay FR
Phone Number
33.1.39.46.51.04

Novacyt Historic Prices and Volume

CurrencyGBP
Issue CountryGB
52 Week Range£2.10 - £12.25
52 Week Change-£0.01
50 Day Moving Average£5.41
200 Day Moving Average£7.80
Average 10 Day Volume1165193
Average 30 Day Volume2101174
5 Day % Change-11%
30 Day % Change-40%
3 Month % Change-49%
6 Month % Change-61%
1 Year % Change-3%
2 Year % Change2,401%
5 Year % Change593%
Year To Date % Change-52%

© 2021 shareprice.ie

While Shareprice.ie does what we can to maintain the high quality of the information displayed on this site, we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.